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Foxp3+ regulatory T cells (Tregs) are a constitutively immunosuppressive cell type critical
for the control of autoimmunity and inﬂammatory pathology. A range of mechanisms of
Treg suppression have been identiﬁed and it has not always been clear how these different
mechanisms interact in order to properly suppress autoimmunity and excessive inﬂamma-
tion. In recent years it has become clear that, while all Tregs seem to share some core
suppressive mechanisms, they are also able to adapt to their surroundings in response
to a variety of stimuli by homing to the sites of inﬂammation and exerting ancillary sup-
pressive functions. In this review, we discuss the relevance and possible modes of Treg
adaptability and put forward a modular model ofTreg suppressive function. Understanding
this ﬂexibility may hold the key to understanding the full spectrum of Treg suppressive
behavior.
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INTRODUCTION
T-regulatory cells (Tregs) are a suppressive subset of T cells, which
make up around 10% of CD4+ cells, crucial to the proper main-
tenance of immune self-tolerance and homeostasis. Natural Tregs
are produced in the thymus but some Tregs may also be induced
in the periphery (Sakaguchi et al., 2008). Since the discovery that
CD25-expressing T cells in the normal immune system have sup-
pressive function (Sakaguchi et al., 1995), the ﬁeld of regulatory
T cells has advanced with the discovery that the transcription
factor Foxp3 is critical to the suppressive function of Tregs as illus-
trated by the ﬁnding that ectopic expression of Foxp3 can induce
regulatory function in naïve T cells (Fontenot et al., 2003; Hori
et al., 2003). A loss of Foxp3 function results in Treg deﬁciency
or dysfunction and is responsible for the autoimmune disorders
seen in both Scurfy mice (Brunkow et al., 2001; Khattri et al.,
2003) and the human immune dysregulation, polyendocrinopa-
thy, enteropathy, X-linked syndrome (IPEX) syndrome (Wildin
et al., 2001). Foxp3 regulates expression of a large number of genes
including those responsible for key features of Tregs, such as an
absence of IL-2 production and high expression of cytotoxic T
lymphocyte antigen-4 (CTLA-4) and CD25. While it has been
clear for some time that Tregs are critical to the maintenance of
immune self-tolerance and homeostasis, the exact mechanisms
by which they are able to do this has been a source of consider-
able debate (Rudensky and Campbell, 2006; Sakaguchi et al., 2009;
Shevach, 2009).
CORE MECHANISMS OF Treg SUPPRESSION
A number of different Treg suppressive mechanisms have been
proposed. It seems that in part this is due to Tregs being
able to adapt to environmental cues and alter their suppres-
sive mechanisms to ﬁt the circumstances. However, while there
is some heterogeneity of function, all Foxp3-expressing Tregs
may share a set of core suppressive mechanisms. As discussed
below, CTLA-4 and IL-2 are most stably activated or repressed,
respectively, by Foxp3 and appear to be involved in such core
mechanisms.
CTLA-4-DEPENDENT SUPPRESSION
CTLA-4 is constitutively expressed by Foxp3+ Tregs and competes
with the closely related CD28 for binding with the co-stimulatory
molecules, CD80 and CD86, on the surface of APCs. While CTLA-
4 is also expressed on activated T-effector cells, mice with a Treg
speciﬁc CTLA-4 depletion suffer from fatal lymphoproliferative
disease, similar to that seen in totally CTLA-4-deﬁcient mice,
despite the development of Tregs in normal numbers (Waterhouse
et al., 1995; Wing et al., 2008). CTLA-4-deﬁcient Tregs also show
impaired in vitro suppressive activity (Wing et al., 2008), while
mice with mixed bone marrow chimeras of CTLA-4-deﬁcient and
sufﬁcient donors do not develop autoimmune disease, demon-
strating cell extrinsic function (Bachmann et al., 1999). For some
time the mechanisms of CTLA-4 function have been obscure but
recent work has elegantly demonstrated that CTLA-4-mediated
trans-endocytosis and degradation of CD80/86 from the surface
of APCs is a key mechanism of CTLA-4 function (Qureshi et al.,
2011). However, this may not be the sole mechanism of CTLA-
4 function as CTLA-4 ligation of CD80/86 also induces nuclear
translocationof the transcription factor Foxo3 inhibiting dendritic
cell (DC) expression of IL-6 and TNFα, while Foxo3 KO mice have
enhanced CD80/86 expression (Dejean et al., 2009). In addition,
CTLA-4 engagement may cause DCs to express the immunosup-
pressive tryptophan catabolizing enzyme IDO (Grohmann et al.,
2002). These ﬁndings collectively suggest that CTLA-4 is critical
to the suppressive function of Tregs and appears to act primarily
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via cell extrinsic effects on APCs (Wing et al., 2008) in which Treg
expression of CTLA-4 reduces APC expression of CD80 and 86
thus reducing their co-stimulatory capacity (Wing et al., 2011).
IL-2-DEPENDENT SUPPRESSION
Several cardinal features of Foxp3+ Tregs are their absence of
IL-2 production, constitutively high expression of the alpha chain
receptor for IL-2 (CD25) and consequent ability to bind IL-2 with
high afﬁnity (Sakaguchi et al., 2007). A central role for IL-2 in Treg
biology has been demonstrated by in vivo studies of mice either
deﬁcient in IL-2 production (Schorle et al., 1991) or IL-2 recep-
tor (Suzuki et al., 1995;Willerford et al., 1995): both suffer from
fatal lymphoproliferative disease in a manner similar to Foxp3-
deﬁcient scurfy mice. Tregs are able to suppress both IL-2 mRNA
and protein production by responder T cells (Takahashi et al.,
1998; Thornton and Shevach, 1998), most likely indirectly due to
a CTLA-4-mediated reduction in CD80/86 co-stimulation from
APCs and also consume IL-2, thus denying it to local T-effector
cells (de la Rosa et al., 2004). This may in turn lead to arrest of pro-
liferation and apoptosis of T-effector cells (Pandiyan et al., 2007).
Since Tregs are dependent on exogenous IL-2 for their survival and
function (Furtado et al., 2002; Setoguchi et al., 2005) but suppress
its production by T cells, it seems that IL-2 is used as a feedback
mechanism topreventTreg overgrowth thatmight otherwise result
in excessive immunosuppression.
Foxp3 regulated features of Treg biology such as high expression
of CTLA-4, CD25 and an absence of IL-2 production are critical
to the function of Tregs, efﬁciently controlling APC-dependent
activation and proliferation of T cells. As a result, knockout of
either CTLA-4 or CD25 expression replicates the phenotype of
Foxp3-deﬁcient mice. However, in addition to this “core module”
of suppression, Foxp3+ Tregs are also able to adapt to their envi-
ronment and take on additional suppressive functions in order
to ﬁt the immune context they ﬁnd themselves in. This may
be of particular importance in the more inﬂammatory condi-
tions found at barrier sites such as the gut in which CTLA-4
and IL-2-based suppression may be sometimes overwhelmed due
to an excess of inﬂammatory signals leading to a requirement
for additional mechanisms such as IL-10 (Rubtsov et al., 2008;
Yamaguchi et al., 2011).
ADAPTABILITY OF SUPPRESSIVE MECHANISMS AND
INDUCTION OF ADDITIONAL TRANSCRIPTION FACTORS
CTLA-4-dependent suppression is not the only mechanism by
which Tregs are able to suppress the activity of other cells. In vitro
experiments give a clear indication of this: while normal Tregs
suppress T-effector proliferation in a CTLA-4-dependent man-
ner, Tregs derived from total CTLA-4-deﬁcient mice also retain
in vitro suppressive capacity. In this case it seems likely that
Tregs derived from CTLA-4-deﬁcient mice are highly activated
due to the ongoing autoimmune pathology and as such may have
induced suppressive functions such as IL-10 andTGFβ secretion. A
wide range of other suppressive molecules have been identiﬁed in
Tregs including: IL-10, TGFβ, Galectin, Neuropilin, IL-35, cAMP,
Granzyme-B, perforin, and cAMP (Sakaguchi et al., 2009; She-
vach, 2009). Many of these molecules are upregulated in effector
CD44high Tregs.
In addition to adopting an effector phenotype in response to
stimulation, recent work has demonstrated that Tregs are able to
adapt to environmental signals and further differentiate from their
base state by expression of transcription factors normally associ-
ated with other T cell subsets (Campbell and Koch, 2011). It seems
likely that Tregs share much of the same molecular machinery as
conventional CD4+ T cells and respond to the same differentia-
tion stimuli. This induction/co-opting of additional transcription
factors seems to be critical to Treg suppression of particular T cell
subsets and their associated immunopathology.
T-bet – Th1
Koch et al. (2009) have demonstrated that the transcription fac-
tor T-bet, normally required for the linage development of Th1
cells, is upregulated in Tregs in response to IFNγ, suggesting
that the induction of this Treg subset occurs in reaction to a
Th1 immune response (Koch et al., 2009). T-bet causes the Th1-
associated chemokine receptor CXCR3 to be upregulated on the
surface of Tregs and a small increase in IFNγ expression was also
observed. CXCR3 homes the cell to the sites of Th1 inﬂamma-
tion via its IFNγ-induced ligands CXCL9, CXCL10, and CXCL11,
allowing Tregs to provide in situ suppression. T-bet-deﬁcient
Tregs are unable to accumulate at the sites of Th1 inﬂamma-
tion and properly control the Th1 immune response (Koch et al.,
2009). In addition, T-bet-deﬁcient Tregs retain their in vitro sup-
pressive activity (Bettelli et al., 2004) and in vivo have only a
modest (approximately 50%) reduction in mRNA expression of
the effector molecules, IL-10 and TGFβ (Koch et al., 2009). This
suggests that the primary role of T-bet in Treg suppression of
Th1 responses may be the control of CXCR3 expression and Treg
localization.
IRF4 AND GATA-3 – Th2
The transcription factor interferon regulatory factor 4 (IRF4) is
critical for the differentiation of Th2 cells and may also play a
role in the differentiation of Th17 cells (Lohoff et al., 2002; Brus-
tle et al., 2007). Foxp3 is able to bind to the promoter region of
IRF4 and enhance its expression (Zheng et al., 2009). Additionally,
Treg-speciﬁc deletion of Irf4 prevents Tregs from efﬁciently sup-
pressing Th2 immune responses leading to an uncontrolled Th2
immune response characterized by signiﬁcantly enhanced IL-4
and IL-5 production, but not IFNγ, IL-2, or IL-17 (Zheng et al.,
2009). Additionally, IRF4-deﬁcient Tregs have decreased expres-
sion of the genes encoding the suppressive molecules IL-10 and
GranzymeB,while also reducingCCR8 expression, the chemokine
receptor important for migration to the sites of Th2 inﬂammation
(Zheng et al., 2009).
Cretney et al. (2011) demonstrated awider role for IRF4 expres-
sion with the ﬁnding that IRF4 may also be required for T-bet and
Blimp-1 expression. Blimp-1 is a transcriptional repressor nor-
mally associated with plasma cell differentiation, but in Tregs it
appears to be crucial to the expression of IL-10 (Cretney et al.,
2011). This would suggest that IRF4 expression by Tregs may also
be critical to IL-10-dependent effector mechanisms. As a result it
seems likely that part of the reason for the failure of IRF4-deﬁcient
Tregs to regulate Th2 responses may be due to a lack of IL-10
production.
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It has also become clear that the canonical Th2 transcription
factor, GATA-3, may also expressed by Tregs (Campbell, 2011;
Wang et al., 2011; Wohlfert et al., 2011). In GATA-3-deﬁcient
Tregs, expression of Foxp3 and constitutively expressedTregmark-
ers/effector molecules such as CLTA-4, GITR, and CD25 were all
reduced both at the mRNA and protein levels. GATA-3-deﬁcient
Tregs are unable to prevent the induction of systemic lympho-
proliferative disease and increased production of Th1, Th2, and
Th17 cytokines (Wang et al., 2011). Thus, unlike STAT3 and T-bet,
whose expression in Tregs appears to be largely linked to the
control of the T cell subtypes with which they are associated, it
seems that GATA-3 has a wider function in the maintenance of
immunity. This is perhaps not surprising as while GATA-3 is often
primarily associated with Th2 cells, it is also expressed in a range
of other cell types and is required for thymocyte development
(Pai et al., 2003).
BCL-6 – T-FOLLICULAR
During a T-dependent immune response CD4+ T cells are able
to express the transcription factor BCL-6 that converts them to a
PD-1+ CXCR5+ T-follicular helper subtype (Tfh; Crotty, 2011).
These cells then home to the follicle, due to the action of the
chemokine receptor CXCR5 guided by CXCL13 produced by fol-
licular stromal cells, and specialize in assisting B cell afﬁnity
maturation and memory cell formation within the germinal cen-
ter (Crotty, 2011). Recent work has demonstrated that thymically
derived Tregs are also able to effectively mimic this phenotype
by induction of BCL-6 giving a CXCR5+ PD-1+ phenotype that
home to the follicular region. These cells appear to differentiate
from thymically produced Tregs in response to the same SLAM-
associated protein (SAP), CD28, and B cell-dependent signals that
induce Tfh differentiation (Chung et al., 2011; Linterman et al.,
2011). This follicular Treg subset then travels to the germinal cen-
ter and controls the germinal center reaction (Chung et al., 2011;
Linterman et al., 2011; Wollenberg et al., 2011). At this time the
primary suppression mechanisms used by follicular Tregs are not
clear, although CTLA-4 protein levels and IL-10 mRNA expres-
sion is increased, while Granzyme B is reduced in comparison to
normal Tregs (Linterman et al., 2011). Surprisingly, given their
expression of BCL-6, normally a mutual repressor of Blimp-1,
these cells also express high levels of prdm1 mRNA encoding the
transcriptional repressor Blimp-1 (Chung et al., 2011; Linterman
et al., 2011) crucial to the expression of IL-10.
STAT3 AND RORγt – Th17
The transcription factor STAT3 is essential for the proper develop-
ment of Th17 cells (Mathur et al., 2007). More recently a role for
STAT3 in Treg biology has been demonstrated by the ﬁnding that
STAT3-deﬁcient Tregs are unable to prevent fatal Th17-mediated
colitis (Chaudhry et al., 2009). Interestingly, these Tregs retain
in vitro suppressive capacity, presumably due to intact CTLA-
4 function, but have reduced expression of IL-10, IL-35, and
CCR6 (Chaudhry et al., 2009). STAT3 phosphorylation by Tregs
is induced in an IL-10-dependent manner with IL-10 receptor-
deﬁcient Tregs failing to phosphorylate STAT3 and restrain
Th17 responses and the development of colitis (Chaudhry et al.,
2011). Additionally, IL-10 receptor (IL10R) expression by Th17
cells is critical for prevention of their inﬂammatory pathology
(Huber et al., 2011).
A number of groups have reported that Tregs may be able to
simultaneously express Foxp3 and the Th17 deﬁning transcrip-
tion factor RORγt, and may produce IL-17 (Zhou et al., 2008;
Voo et al., 2009; Hovhannisyan et al., 2011). In humans, Tregs
have been observed to lose suppressive function while produc-
ing IL-17 but then regain suppressive function, suggesting that
this could be a temporary loss of suppressive capability in order
to allow the immune response sufﬁcient time to effectively ﬁght
pathogens before suppressive function is re-established (Beriou
et al., 2009). Interestingly, only CCR6-expressing Tregs expressed
IL-17 (Beriou et al., 2009). This is of relevance sinceCCR6 controls
Treg accumulation at the sites of Th17-mediated inﬂammation
due to the IL-17-mediated release of its ligand CCL20 by epithelial
cells (Hirota et al., 2007; Yamazaki et al., 2008).
SYNTHESIS
While all Tregs can be characterized as Foxp3+ CTLA-4+ and
lacking IL-2 production, it seems that from this base state a range
of transcription factors may be induced/co-opted in order to allow
the Treg to adapt to inﬂammatory cues. It seems likely that Tregs
share much of the same molecular machinery as conventional
CD4+ T cells and thus respond to the same stimuli to differentiate
into Thχ-like Tregs.
In this sense there is a core module of Treg suppression driven
by Foxp3 expression that acts to prevent the activation, prolif-
eration, and as a result the differentiation, of T-effector cells.
This core module may be augmented by induction of additional
modules, driven by transcription factors normally associated with
other T cell subsets, allowing Tregs to adapt to become “Thχ-
like”Tregs and deliver suppression to diverse sites within the body
(Figure 1).
While the possibility that someTregsmay lose Foxp3 expression
and become proinﬂammatory “ex-Tregs” is highly controversial
(Zhou et al., 2009; Rubtsov et al., 2010; Hori, 2011; Miyao et al.,
2012), we should perhaps not be surprised to ﬁnd some evidence
of proinﬂammatory cytokine expression by Thχ-like Tregs that
broadly retain suppressive function. While Foxp3 is a master reg-
ulator it does not totally repress the loci associated with Th1,
Th2, and Th17 cytokines (Wei et al., 2009; Duhen et al., 2012).
As a result it is not necessarily a contradiction to ﬁnd Tregs-
expressing proinﬂammatory cytokines and it will be interesting
to see if in some settings there are beneﬁts to Treg expression
of proinﬂammatory cytokines. For example, Treg expression of
IFNγ has been reported in several settings; during infection with
Toxoplasma gondii IFNγ-producing Tregs retained their in vitro
suppressive capacity (Oldenhove et al., 2009) while IL-12-induced
IFNγ-producing Tregs retain both in vitro suppressive capacity
and the ability to prevent colitis in an IFNγ-dependent manner
(Feng et al., 2011). Treg produced IFNγ may also have a protec-
tive role in transplant tolerance. Alloreactive Tregs are able to
prevent rejection of a BALB/c skin graft in C57/B6 mice, while
Tregs from IFNγ-deﬁcient mice were signiﬁcantly less protective
(Sawitzki et al., 2005).
Thχ-like Tregs appear to have an effector Treg phenotype, with
clear roles for IL-10 in STAT-3 and IRF4 driven suppression, while
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FIGURE 1 | A two module model ofTreg function. Foxp3 acts to control
the core module of Treg suppressive function by regulating expression of a
number of key molecules such as CTLA-4 and CD25. This allowsTregs to
suppressT-effector activation and proliferation by suppressing APC function
via CTLA-4 and possibly depriving IL-2 from other T cells. An additional
Thχ-like module of suppressive function may also be induced that causes
Tregs to expressThχ-like transcription factors allowing theTregs to take on
some of the properties of Th1, Th2, Th17, or follicular T cells, travel to the
same sites and deliver in situ suppression.
T-bet and BCL-6-expressing Tregs also seem to have upregulated
expression of IL-10. While IL-10 is not critical to the in vitro
function of Tregs (Takahashi et al., 1998; Rubtsov et al., 2008),
in vivo experiments have demonstrated IL-10 to be important
in the maintenance of immune homeostasis in the gut, with
IL-10-deﬁcient mice spontaneously developing intestinal inﬂam-
mation (Kuhn et al., 1993), while Treg-speciﬁc deletion of il10
leads to colitis and inﬂammation at the lung surface (Rubtsov
et al., 2008), suggesting that its role may be to control excessive
inﬂammation from microbial stimulation at mucosal surfaces
rather than maintenance of self-tolerance. At this time it is not
clear if the suppressive mechanisms employed by Thχ-like Tregs
are different from previously deﬁned effector Tregs, or if the dif-
ferences are primarily due to cell localization. Additionally, it
seems likely that, on close examination of their transcription factor
expression, there may be substantial overlap between previously
identiﬁed effector Tregs and Thχ-like Tregs. As it stands, no clear
mechanisms of suppression that are truly speciﬁc to a particular
Thχ-like Treg have been identiﬁed. As a result, it seems likely that
these are specialized subsets of effector Tregs and the primary role
of the induction of these transcription factors is to allow Tregs
to respond to the same stimuli as conventional T cells, travel to
the same sites, and enhance or upregulate existing effector Treg
suppressive mechanisms such as CTLA-4 and IL-10.
CONCLUSION
While Tregs have a core module of suppression driven by Foxp3
expression, they are also able to adapt to changes in their envi-
ronment and harness additional modules by the expression of
transcription factors normally associated with other T cell sub-
types in order to better control immunopathology. Particularly
in the light of ongoing work examining either transfer or deple-
tion of Tregs in clinical settings it is critical that we understand
both the core functions of Tregs and their range of ﬂexibility that
allows them to modulate their mechanisms of suppression and cell
localization in response to speciﬁc stimuli.
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